UCSF

Current Grants

Building the Evidence Base for Appropriate and Efficient Implementation of Emerging Genomic Tests for Disease Management and Screening

The objective of this award is to assess payer coverage decisions and the economic value of two types of emerging genomic tests for disease management and screening: cfDNA and PRS tests. We will examine which cfDNA and PRS tests are covered and why, address the economic value of cfDNA and PRS tests, and compare evidence needs for payer coverage and economic value assessment across clinical scenarios and generalize our findings on evidence needs to other emerging clinical scenarios.

Funding: NIH/NHGRI (R01HG011792

Timeframe: 07/08/2021– 04/30/2026

Summary: PDF iconOne-pager with grant details

Economic, Financial, and Policy Implications of Genetic Testing for Alzheimer’s Disease and Related Dementias (ADRD)

The objective of this award is to develop conceptual frameworks and methodological approaches to examine the economic, financial/coverage, and policy implications of genetic testing for ADRD risk and conduct initial analyses in the following areas: coverage policies for ADRD genetic testing, role of physicians in managing patients who present their APOE DTC testing results, and economic value of ADRD genetic testing.

Funding: NIH/NCI (R01CA221870-03S1)

Timeframe: 07/01/2020– 06/30/2022

Summary: PDF iconOne-pager with grant details

Coverage, price, and reimbursement for multigene tests for cancer and related conditions

The objective of this award is to examine “coverage, price, and reimbursement” (“CPR”) for cancer risk multigene tests (panels and sequencing tests): what tests are covered by payers, why are tests covered or not covered, and how CPR influences testing decisions and practices in clinic settings.

Funding: NIH/NCI (R01CA221870)

Timeframe: 07/01/2018 – 06/30/2022

Summary:  PDF iconOne-pager with grant details

Genomic sequencing to aid diagnosis in pediatric and prenatal practice

The center grant will focus on generating and analyzing evidence regarding the clinical utility of genome sequencing from the perinatal period into early childhood through examining clinical utility, ethical implications, payer coverage, and data integration in a diverse population.

Funding: NIH/NHGRI (U01HG009599)

Timeframe: 08/01/2017 – 05/31/2022

Summary: PDF iconOne-pager with grant details

Improving precision medicine for breast cancer in Latinas: Enhancing Access to Genetic Testing

The objective of this award is to examine payer coverage and clinical decision-making/access to the use of cancer risk multigene tests (panels and sequencing tests) in the Latina population within the state of California.

Funding: California Initiative to Advance Precision Medicine (CIAPM)

Timeframe: 09/01/2019– 07/30/2022

Summary: PDF iconOne-pager with grant details

Prevention of Fractures in Patients with Parkinson’s Disease

This parent grant will take the form of a large, home-based trial testing the hypotheses that among older patients with Parkinson’s disease a single treatment of zoledronic acid (ZA) will reduce the risk of 1) nonvertebral fractures, 2) hip fracture, and 3) all-cause mortality. TRANSPERS is leading a sub-aim as part of this study to assess the generalizability and interpretation of the economic findings and, as relevant, participate in developing a detailed cost-effectiveness analysis to support the implementation of the intervention in broader health care settings.

Funding: NIH/NIA (RO1AG059417)

Timeframe: 09/30/2018 – 02/28/2024

Summary: PDF iconOne-pager with grant details

Selected Previous Grants

Risk-benefit trade-offs for whole genome sequencing

The objective of this award was to evaluate the benefit-risk trade-offs of genomic sequencing technologies from an individual perspective -how patients make decisions about sequencing and from a societal perspective - how sequencing may impact the health care system.

Funding: NIH/NHGRI (R01HG007063)

Timeframe: 2013 – 2019

Developing evidence on reimbursement for the UCSF500 tumor profiling panel test

Our objective was to collect evidence on reimbursement challenges for Cancer Tumor Profiling (UCSF500) tests and explore how those challenges could be addressed. The goal is to obtain preliminary data and develop a multi-disciplinary team of collaborators that can compete for larger grant funding.

Funding: UCSF Research Administration Program

Timeframe: 2017 – 2018

Supplement: Who is Paying, Will be Paying, and Should be Paying for Genomic Sequencing?

The objective of this supplement was to systematically assess coverage and reimbursement of sequencing tests (gene panels, whole exome sequencing, and whole genome sequencing) as they move into clinical care, using insights developed from an analysis of coverage policies for established tests already in clinical use and a multi-stakeholder technical working group. ​

Funding: NIH/NHGRI (R01HG007063-02S1)

Timeframe: 2014 – 2016

Transdisciplinary Translational Team Grant: Moving Cancer Genomics Into Clinical Care

The objective of this award was to identify fundable research questions and studies - using a collaborative, transdisciplinary, and translational approach- on factors influencing adoption of cancer genomic analysis, using UCSF as a case study and focusing on “next generation tumor sequencing” (NGTS).

Funding: UCSF Cancer Center

Timeframe: 2013 – 2014

Personalized Medicine for Breast and Colorectal Cancer (Program Project Grant)

The objective of this Program Project Grant was to address personalized medicine - health care targeting medical interventions to patients based on their individual characteristics, particularly their genetics. The objective was to use an integrated, interdisciplinary approach to obtain evidence about key aspects of the translation of genomic information for breast and colorectal cancer into clinical practice and health policy.

Funding: NIH/NCI (P01CA130818)

Timeframe: 2008 – 2013

 

Learn more about our work

Subscribe to our newsletter by emailing [email protected].